Article
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.
PloS one - 1 Jan 2016
Pogue Sarah L, Taura Tetsuya, Bi Mingying, Yun Yong, Sho Angela, Mikesell Glen, Behrens Collette, Sokolovsky Maya, Hallak Hussein, Rosenstock Moti, Sanchez Eric, Chen Haiming, Berenson James, Doyle Anthony, Nock Steffen, Wilson David S
Abstract excerpt
Interferon-α (IFNα) has been prescribed to effectively treat multiple myeloma (MM) and other malignancies for decades. Its use has waned in recent years, however, due to significant toxicity and a narrow therapeutic index (TI). We sought to improve IFNα's TI by, first, attaching it to an anti-CD38 antibody, thereby directly targeting it to MM cells, and, second, by introducing an attenuating mutation into the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.